|
AzurRx BioPharma Announces Formation of Scientific Advisory Board
|
21 Oct, 2020 |
|
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis
|
14 Oct, 2020 |
|
AzurRx BioPharma CEO Issues Letter to Shareholders
|
07 Oct, 2020 |
|
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
|
15 Sep, 2020 |
|
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
|
31 Aug, 2020 |
|
AzurRx BioPharma to Present at The LD 500 Virtual Conference (September 4th)
|
18 Aug, 2020 |
|
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
|
17 Aug, 2020 |
|
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
|
13 Aug, 2020 |
|
AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders
|
12 Aug, 2020 |
|
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
|
11 Aug, 2020 |
|
AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
|
22 Jul, 2020 |
|
AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange
|
20 Jul, 2020 |
|
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
|
07 May, 2020 |
|
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
|
05 May, 2020 |
|
AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
|
30 Apr, 2020 |
|
AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites
|
29 Apr, 2020 |
|
AzurRx BioPharma Issues Letter to Shareholders
|
21 Apr, 2020 |
|
Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX)
|
20 Apr, 2020 |
|
AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product
|
16 Apr, 2020 |
|
AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
|
15 Apr, 2020 |
|
AzurRx Appoints Gregory Oakes to its Board of Directors
|
09 Apr, 2020 |
|
AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)
|
01 Apr, 2020 |
|
AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th
|
18 Mar, 2020 |
|
AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)
|
02 Mar, 2020 |
|
AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference
|
18 Feb, 2020 |
|
AzurRx BioPharma Announces Closing of $6.9 Million Private Placement
|
13 Jan, 2020 |
|
AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco
|
10 Jan, 2020 |
|
AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)
|
06 Jan, 2020 |
|
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer
|
03 Jan, 2020 |
